Skip to main content
Top
Published in: Journal of Infection and Chemotherapy 3/2013

01-06-2013 | Surveillance

Nationwide surveillance of bacterial pathogens from patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2009 and 2010: antimicrobial susceptibility of Escherichia coli and Staphylococcus saprophyticus

Authors: Hiroshi Hayami, Satoshi Takahashi, Kiyohito Ishikawa, Mitsuru Yasuda, Shingo Yamamoto, Shinya Uehara, Ryoichi Hamasuna, Tetsuro Matsumoto, Shinichi Minamitani, Akira Watanabe, Aikichi Iwamoto, Kyoichi Totsuka, Junichi Kadota, Keisuke Sunakawa, Junko Sato, Hideaki Hanaki, Taiji Tsukamoto, Hiroshi Kiyota, Shin Egawa, Kazushi Tanaka, Soichi Arakawa, Masato Fujisawa, Hiromi Kumon, Kanao Kobayashi, Akio Matsubara, Seiji Naito, Katsunori Tatsugami, Takamasa Yamaguchi, Shin Ito, Mototsugu Kanokogi, Harunori Narita, Hiromi Kawano, Takahide Hosobe, Kazuo Takayama, Toru Sumii, Akira Fujii, Takashi Sato, Takamine Yamauchi, Masanobu Izumitani, Hirofumi Chokyu, Hideari Ihara, Kikuo Akiyama, Masaru Yoshioka, Satoshi Uno, Koichi Monden, Motonori Kano, Shinichi Kaji, Shuichi Kawai, Kenji Ito, Hisato Inatomi, Hirofumi Nishimura, Toshihiro Ikuyama, Shohei Nishi, Koichi Takahashi, Yukihiro Kawano, Satoshi Ishihara, Kengo Tsuneyoshi, Shinji Matsushita, Takashi Yamane, Takaoki Hirose, Shigeru Fujihiro, Katsuhisa Endo, Yasuhiko Oka, Koh Takeyama, Takahiro Kimura, Tetsuji Uemura

Published in: Journal of Infection and Chemotherapy | Issue 3/2013

Login to get access

Abstract

The Japanese surveillance committee conducted the first nationwide surveillance of antimicrobial susceptibility patterns of uropathogens responsible for female acute uncomplicated cystitis at 43 hospitals throughout Japan from April 2009 to November 2010. In this study, the causative bacteria (Escherichia coli and Staphylococcus saprophyticus) and their susceptibility to various antimicrobial agents were investigated by isolation and culturing of bacteria from urine samples. In total, 387 strains were isolated from 461 patients, including E. coli (n = 301, 77.8 %), S. saprophyticus (n = 20, 5.2 %), Klebsiella pneumoniae (n = 13, 3.4 %), and Enterococcus faecalis (n = 11, 2.8 %). S. saprophyticus was significantly more common in premenopausal women (P = 0.00095). The minimum inhibitory concentrations of 19 antibacterial agents used for these strains were determined according to the Clinical and Laboratory Standards Institute manual. At least 87 % of E. coli isolates showed susceptibility to fluoroquinolones and cephalosporins, and 100 % of S. saprophyticus isolates showed susceptibility to fluoroquinolones and aminoglycosides. The proportions of fluoroquinolone-resistant E. coli strains and extended-spectrum β-lactamase (ESBL)-producing E. coli strains were 13.3 % and 4.7 %, respectively. It is important to confirm the susceptibility of causative bacteria for optimal antimicrobial therapy, and empiric antimicrobial agents should be selected by considering patient characteristics and other factors. However, the number of isolates of fluoroquinolone-resistant or ESBL-producing strains in gram-negative bacilli may be increasing in patients with urinary tract infections (UTIs) in Japan. Therefore, these data present important information for the proper treatment of UTIs and will serve as a useful reference for future surveillance studies.
Literature
1.
go back to reference Yamaguchi K, Ohno A, Levofloxacin Surveillance Group. Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002. Diagn Microbiol Infect Dis. 2005;52:135–43.PubMedCrossRef Yamaguchi K, Ohno A, Levofloxacin Surveillance Group. Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002. Diagn Microbiol Infect Dis. 2005;52:135–43.PubMedCrossRef
2.
go back to reference Yamaguchi K, Furuya N, Iwata M, Watanabe N, Uehara N, Yasujima M, et al. Surveillance of susceptibility of clinical isolates to gatifloxacin and various antimicrobial agents. Jpn J Chemother. 2005;53:627–40. Yamaguchi K, Furuya N, Iwata M, Watanabe N, Uehara N, Yasujima M, et al. Surveillance of susceptibility of clinical isolates to gatifloxacin and various antimicrobial agents. Jpn J Chemother. 2005;53:627–40.
3.
go back to reference Ishikawa K, Matsumoto T, Yasuda M, Uehara S, Muratani T, Yagisawa M, et al. The nationwide study of bacterial pathogens associated with urinary tract infections conducted by the Japanese Society of Chemotherapy. J Infect Chemother. 2011;17:126–38.PubMedCrossRef Ishikawa K, Matsumoto T, Yasuda M, Uehara S, Muratani T, Yagisawa M, et al. The nationwide study of bacterial pathogens associated with urinary tract infections conducted by the Japanese Society of Chemotherapy. J Infect Chemother. 2011;17:126–38.PubMedCrossRef
4.
go back to reference Matsumoto T, Hamasuna R, Ishikawa K, Takahashi S, Yasuda M, Hayami H, et al. Nationwide survey of antibacterial activity against clinical isolates from urinary tract infections in Japan (2008). Int J Antimicrob Agents. 2011;37:210–8.PubMedCrossRef Matsumoto T, Hamasuna R, Ishikawa K, Takahashi S, Yasuda M, Hayami H, et al. Nationwide survey of antibacterial activity against clinical isolates from urinary tract infections in Japan (2008). Int J Antimicrob Agents. 2011;37:210–8.PubMedCrossRef
5.
go back to reference Committee on Revision of UTI Drug Efficacy Evaluation Standards. Japanese Society of Chemotherapy: guidelines for clinical trials on genitourinary tract infections, version 1. Jpn J Chemother. 2009;57:511–25. Committee on Revision of UTI Drug Efficacy Evaluation Standards. Japanese Society of Chemotherapy: guidelines for clinical trials on genitourinary tract infections, version 1. Jpn J Chemother. 2009;57:511–25.
6.
go back to reference Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne: CLSI; 2006. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne: CLSI; 2006.
7.
go back to reference Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. Document M100-S17. Wayne: CLSI; 2007. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. Document M100-S17. Wayne: CLSI; 2007.
8.
go back to reference Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline. Document M45-A. Wayne: CLSI; 2006. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline. Document M45-A. Wayne: CLSI; 2006.
9.
go back to reference Hanaki H, Kubo R, Nakano T, Kurihara M, Sunagawa K. Characterization of HMRZ-86: a novel chromogenic cephalosporin for the detection of extended-spectrum beta-lactamases. J Antimicrob Chemother. 2004;53:888–9.PubMedCrossRef Hanaki H, Kubo R, Nakano T, Kurihara M, Sunagawa K. Characterization of HMRZ-86: a novel chromogenic cephalosporin for the detection of extended-spectrum beta-lactamases. J Antimicrob Chemother. 2004;53:888–9.PubMedCrossRef
10.
go back to reference Colodner R, Reznik B, Gal V, Yamazaki H, Hanaki H, Kubo R. Evaluation of a novel kit for the rapid detection of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 2006;25:49–51.PubMedCrossRef Colodner R, Reznik B, Gal V, Yamazaki H, Hanaki H, Kubo R. Evaluation of a novel kit for the rapid detection of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 2006;25:49–51.PubMedCrossRef
11.
go back to reference Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. Document M100-S18. Wayne: CLSI; 2008. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. Document M100-S18. Wayne: CLSI; 2008.
12.
go back to reference Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113:5S–13S.PubMedCrossRef Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113:5S–13S.PubMedCrossRef
13.
go back to reference Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother. 2003;51:69–76.PubMedCrossRef Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother. 2003;51:69–76.PubMedCrossRef
14.
go back to reference Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009;34:407–13.PubMedCrossRef Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009;34:407–13.PubMedCrossRef
15.
go back to reference Shigemura K, Tanaka K, Adachi M, Yamashita M, Arakawa S, Fujisawa M. Chronological change of antibiotic use and antibiotic resistance in Escherichia coli causing urinary tract infections. J Infect Chemother. 2011;17:646–51.PubMedCrossRef Shigemura K, Tanaka K, Adachi M, Yamashita M, Arakawa S, Fujisawa M. Chronological change of antibiotic use and antibiotic resistance in Escherichia coli causing urinary tract infections. J Infect Chemother. 2011;17:646–51.PubMedCrossRef
16.
go back to reference Acar CF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis. 1997;24:S67–73.PubMedCrossRef Acar CF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis. 1997;24:S67–73.PubMedCrossRef
17.
go back to reference Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med. 1993;329:1328–34.PubMedCrossRef Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med. 1993;329:1328–34.PubMedCrossRef
18.
go back to reference Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med. 2002;113:14S–9S.PubMedCrossRef Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med. 2002;113:14S–9S.PubMedCrossRef
19.
go back to reference Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents. 2012;39(1):45–51.PubMedCrossRef Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents. 2012;39(1):45–51.PubMedCrossRef
20.
go back to reference Raz R, Colodner R, Kunin CM. Who are you—Staphylococcus saprophyticus? Clin Infect Dis. 2005;40:896–8.PubMedCrossRef Raz R, Colodner R, Kunin CM. Who are you—Staphylococcus saprophyticus? Clin Infect Dis. 2005;40:896–8.PubMedCrossRef
21.
go back to reference Killgore KM, March KL, Gugleilmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother. 2004;38:1148–52.PubMedCrossRef Killgore KM, March KL, Gugleilmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother. 2004;38:1148–52.PubMedCrossRef
22.
go back to reference Kanda H, Kurosaka Y, Fujikawa K, Chiba M, Yamachika S, Okumura R, et al. In vitro and in vivo antibacterial activity of sitafloxacin. Jpn J Chemother. 2008;56:1–17. Kanda H, Kurosaka Y, Fujikawa K, Chiba M, Yamachika S, Okumura R, et al. In vitro and in vivo antibacterial activity of sitafloxacin. Jpn J Chemother. 2008;56:1–17.
23.
go back to reference Yamamoto S, Higuchi Y, Nojima M. Current therapy of acute uncomplicated cystitis. Int J Urol. 2010;17:450–6.PubMedCrossRef Yamamoto S, Higuchi Y, Nojima M. Current therapy of acute uncomplicated cystitis. Int J Urol. 2010;17:450–6.PubMedCrossRef
24.
go back to reference Ishikawa K, Hayakawa S, Miyakawa S, Kusaka M, Shiroki R, Hoshinaga K. Survey of the susceptibility of urinary isolates to antibacterial agents in 2003. J Infect Chemother. 2005;11:44–7.PubMedCrossRef Ishikawa K, Hayakawa S, Miyakawa S, Kusaka M, Shiroki R, Hoshinaga K. Survey of the susceptibility of urinary isolates to antibacterial agents in 2003. J Infect Chemother. 2005;11:44–7.PubMedCrossRef
25.
go back to reference Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Cell. 2007;128:1037–50.PubMedCrossRef Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Cell. 2007;128:1037–50.PubMedCrossRef
26.
go back to reference Rupp ME, Soper DE, Archer GL. Colonization of the female genital tract with Staphylococcus saprophyticus. J Clin Microbiol. 1992;30:2975–9.PubMed Rupp ME, Soper DE, Archer GL. Colonization of the female genital tract with Staphylococcus saprophyticus. J Clin Microbiol. 1992;30:2975–9.PubMed
27.
go back to reference Latham RH, Running K, Stamm WE. Urinary tract infections in young adult women caused by Staphylococcus saprophyticus. JAMA. 1983;250:3063–6.PubMedCrossRef Latham RH, Running K, Stamm WE. Urinary tract infections in young adult women caused by Staphylococcus saprophyticus. JAMA. 1983;250:3063–6.PubMedCrossRef
28.
go back to reference Jellheden B, Norrby RS, Sandberg T. Symptomatic urinary tract infection in women in primary health care: bacteriological, clinical and diagnostic aspects in relation to host response to infection. Scand J Prim Health Care. 1996;14:122–8.PubMedCrossRef Jellheden B, Norrby RS, Sandberg T. Symptomatic urinary tract infection in women in primary health care: bacteriological, clinical and diagnostic aspects in relation to host response to infection. Scand J Prim Health Care. 1996;14:122–8.PubMedCrossRef
29.
go back to reference Saginur R, Nicolle LE. Single-dose compared with 3-day norfloxacin treatment of uncomplicated urinary tract infection in women. Canadian Infectious Diseases Society Clinical Trials Study Group. Arch Intern Med. 1992;152:1233–7.PubMedCrossRef Saginur R, Nicolle LE. Single-dose compared with 3-day norfloxacin treatment of uncomplicated urinary tract infection in women. Canadian Infectious Diseases Society Clinical Trials Study Group. Arch Intern Med. 1992;152:1233–7.PubMedCrossRef
Metadata
Title
Nationwide surveillance of bacterial pathogens from patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2009 and 2010: antimicrobial susceptibility of Escherichia coli and Staphylococcus saprophyticus
Authors
Hiroshi Hayami
Satoshi Takahashi
Kiyohito Ishikawa
Mitsuru Yasuda
Shingo Yamamoto
Shinya Uehara
Ryoichi Hamasuna
Tetsuro Matsumoto
Shinichi Minamitani
Akira Watanabe
Aikichi Iwamoto
Kyoichi Totsuka
Junichi Kadota
Keisuke Sunakawa
Junko Sato
Hideaki Hanaki
Taiji Tsukamoto
Hiroshi Kiyota
Shin Egawa
Kazushi Tanaka
Soichi Arakawa
Masato Fujisawa
Hiromi Kumon
Kanao Kobayashi
Akio Matsubara
Seiji Naito
Katsunori Tatsugami
Takamasa Yamaguchi
Shin Ito
Mototsugu Kanokogi
Harunori Narita
Hiromi Kawano
Takahide Hosobe
Kazuo Takayama
Toru Sumii
Akira Fujii
Takashi Sato
Takamine Yamauchi
Masanobu Izumitani
Hirofumi Chokyu
Hideari Ihara
Kikuo Akiyama
Masaru Yoshioka
Satoshi Uno
Koichi Monden
Motonori Kano
Shinichi Kaji
Shuichi Kawai
Kenji Ito
Hisato Inatomi
Hirofumi Nishimura
Toshihiro Ikuyama
Shohei Nishi
Koichi Takahashi
Yukihiro Kawano
Satoshi Ishihara
Kengo Tsuneyoshi
Shinji Matsushita
Takashi Yamane
Takaoki Hirose
Shigeru Fujihiro
Katsuhisa Endo
Yasuhiko Oka
Koh Takeyama
Takahiro Kimura
Tetsuji Uemura
Publication date
01-06-2013
Publisher
Springer Japan
Published in
Journal of Infection and Chemotherapy / Issue 3/2013
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-013-0606-9

Other articles of this Issue 3/2013

Journal of Infection and Chemotherapy 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.